Omega-3 Oil Use in COVID-19 Patients in Qatar

• Status: Recruiting
• Trial end date: 2021-12-24
• Target enrollment: 0
• Participant gender: All

Summary

COVID-19 infection has been widely spread since December 2019 and causing many comorbidities and fatalities. The most common clinical presentation of COVID-19 patients admitted to ICUs is respiratory failure , hypoxia and acute lung injury.

While new therapies and vaccines are urgently being investigated, they may take an inordinate time to get to right people. Omega-3-oil has been shown to have less proinflammatory mediators that may have immunomodulating, anti-inflammatory and antiviral effect. Two main fatty acids in omega-3-oil including eicosapentaenoic acid and docosahexaenoic acid have shown benefit in patients with ARDS as well.

So, the investigators proposed a randomized controlled study to evaluate the effectiveness of omega-3-oil supplementation 2 gm PO/NGT/OGT twice daily for 28 days or till discharge or till death in COVID-19 critically ill patients admitted to ICU who require oxygen support.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation

Criteria

Inclusion Criteria:

1. adult ICU patients ≥18 years

2. confirmed COVID-19 infection

3. on-Oxygen support (mechanical ventilation, face masks, nasal cannula, etc.)

4. Previous history of omega-3-oil with discontinuation of at least 1 month prior to admission

Exclusion Criteria:

1. soya bean oil allergy

2. fish allergy

3. peanut allergy

4. fish oil allergy

5. pregnant women

6. Continuous use of Omega-3-oil till admission